Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

Item

http://www.wikidata.org/entity/Q33658593

Q33658593

about

Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells Getting TRAIL back on track for cancer therapy Role of nanotechnology and gene delivery systems in TRAIL-based therapies Hyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cells PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.Eculizumab hepatotoxicity in pediatric aHUS.Antibody phage display libraries: contributions to oncology.A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.Evidence for two modes of synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia in human colon cancer cells.A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway Advances in phage display technology for drug discovery.TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab.Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl Clinical targeting of the TNF and TNFR superfamilies TNFRSF10C copy number variation is associated with metastatic colorectal cancer.TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors.Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects Therapeutic applications of TRAIL receptor agonists in cancer and beyond.An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma.TRAIL receptor signaling and therapeutics.Towards novel paradigms for cancer therapy.Radioimmunotherapy of solid tumors: searching for the right target.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Harnessing the cell death pathway for targeted cancer treatment.Recent advances in the application of antibodies as therapeutics.TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.Emerging drugs for cervical cancer.Apoptosis-modulating drugs for improved cancer therapy.

P2860

Q26771601-1BB2A641-629E-4C74-A817-795283CAD4B1 Q26852287-7FB881C9-B8F1-49B5-9EA4-B7D456A54B60 Q27027460-8F372B72-C8F6-40DB-955A-F08B981562E8 Q28076798-267B88C3-F44B-4C9C-BC60-A0B8AB13438C Q28397571-4F13BBF4-3F02-42DC-99E1-652209ADF6BB Q31122542-3EA0E048-7163-4308-87F0-B5235CAF4AE6 Q33418797-29F16D20-BCD9-4A15-85E7-3536137F5166 Q34323991-0B17C596-5F92-4DC9-B4BE-33AB2A3E05CE Q34433792-FD441800-D4BC-4B8D-A684-CEE6CE140366 Q34464915-771B0614-CC61-48DF-B656-D7228C56A732 Q34532108-B8E212B2-3C39-4A7A-B1A9-9D5077BADE57 Q34608366-69BE8CC3-14C0-453F-A46B-076498842AAC Q34980866-0109C758-E4D1-423F-BDF8-B97F9A5A4DDB Q35038107-9CDF0E2B-3C0D-485B-AFF3-30B9FA519F6B Q35595688-3B24F696-3EA8-46C7-A145-F116EE2BB7E9 Q35614190-0F93C111-96BC-4580-888B-8C89B9E88105 Q35681794-5E7C2CB5-E5E4-4918-AE35-CE51FBB7FDBC Q35951059-F23A1C50-3BC0-4D3A-9CCE-9A7B6C571DCD Q36215003-569E9C9F-7FC7-406E-BD19-70DF8F5D63CF Q36366424-8EA11C56-41A4-485E-A121-C61A10BA5EB7 Q36395984-3F36313C-0CAE-4808-B84E-382CBD40D85F Q36580632-D6E1E8FD-A922-4A69-9FA0-5223FFB68184 Q36762882-A8814FDD-42D9-4843-BAFB-E37385329798 Q36936939-5074B85F-A1A9-4EDB-A335-105CF290E319 Q37012681-E0495AD2-DC97-48CC-B79F-96535C736D21 Q37063421-EFDE89DE-AD39-41FA-A25B-800B73A88455 Q37071019-D20DA745-5949-4253-8D22-700A5C71F8C7 Q37073589-3B71773A-63FE-4D81-9F36-B546FAA07DB1 Q37114025-ACB2A8C7-4AE3-42D0-A258-30D58B95F368 Q37141627-80CF8394-791C-4D7D-9C93-7B421F3B080F Q37492231-D4D72DEE-D724-460A-9805-D922FBFB65B9 Q37785559-BA12D526-3931-482A-9F92-CAE882D624E5 Q37799251-AF14157F-22F3-4997-99D3-9816A57B8CC3 Q37804904-183539E4-DAE6-4595-9801-F5322BEC46FC Q37913356-E0019328-150A-4BEB-AC8F-8EB1FC363730 Q37942090-624604E1-198E-4163-A671-6ADAD937E3EF Q37968255-6E3BD759-5C6E-4DEF-BDC8-6703268B0FC6 Q37972139-A2EF728C-59D8-46FC-8E39-8151FBD80D38 Q38005222-C992C51E-8EF7-4BDB-BA38-35A05DC2D16F Q38005914-E370C40E-69A9-49E7-9242-E13541DF4411

P2860

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

Item

http://www.wikidata.org/entity/Q33658593

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu